# Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

Study · id `cardio:ct-nct05731544` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05731544](<https://clinicaltrials.gov/study/NCT05731544>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05731544

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 443 participants.

## Technical summary

Registry record NCT05731544. Randomized; double masking; primary purpose treatment. Start 2022-08-17 (actual); primary completion 2024-11-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 443 participants (enrolled count; ClinicalTrials.gov record NCT05731544, source copy `cardio:ctgov-nct05731544-2026-10-27`, retrieved 2026-10-31)
- Started: 2022-08-17 (actual) (ClinicalTrials.gov record NCT05731544, source copy `cardio:ctgov-nct05731544-2026-10-27`, retrieved 2026-10-31)
- Primary completion: 2024-11-18 (actual) (ClinicalTrials.gov record NCT05731544, source copy `cardio:ctgov-nct05731544-2026-10-27`, retrieved 2026-10-31)
- Completion: 2025-07-08 (actual) (ClinicalTrials.gov record NCT05731544, source copy `cardio:ctgov-nct05731544-2026-10-27`, retrieved 2026-10-31)
- Countries: United States; Canada (ClinicalTrials.gov record NCT05731544, source copy `cardio:ctgov-nct05731544-2026-10-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05731544-2026-10-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): BMF-219
- Intervention (Drug): Placebo
- Lead sponsor: Biomea Fusion Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: df14d7f4cc67d7edb56491916ab7421b65057cfc5b9643c0da1dc593d3a5326b
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
